Ranking Profile - Cogent Biosciences Inc
Introduction
Cogent Biosciences Inc (Cogent Biosciences) formerly, Unum Therapeutics Inc is a clinical-stage biopharmaceutical company that develops and commercializes precision therapies for genetically defined diseases. The company's pipeline product portfolio includes CGT9486 which is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis, a serious disease caused by the unchecked proliferation of mast cells. It carries out clinical trials such as Apex, Summit and Peak. Cogent Biosciences is headquartered in Cambridge, Massachusetts, the US.
Company info
Country (HQ): | United States |
Sector: | Pharmaceuticals and Healthcare |
Market Cap (US$ m): | 792 |
Revenue (US$ m): |
Innovation ranking
Innovation score
Closest peers in the Pharmaceuticals and Healthcare sector
Innovation Ranking
Johnson & Johnson
United States
Pharmaceuticals and Healthcare
F. Hoffmann-La Roche Ltd
Switzerland
Pharmaceuticals and Healthcare
Cogent Biosciences Inc
United States
Pharmaceuticals and Healthcare
EyeGate Pharmaceuticals Inc
United States
Pharmaceuticals and Healthcare
Shin Poong Pharm Co Ltd
South Korea
Pharmaceuticals and Healthcare
Are you ranked? Get the Innovation Ranking Report
-
Company Ranking Report
- If your company is ranked you can get more detailed information about your ranking through the Innovation Ranking Report
- Full company scorecard across the 3 pillars and 19 data indicators that make up the ranking score
- Contextualised information on the company's standing in relation to peers
- Key takeaways on the company's position in its sector, country and its standing in relation to key industry themes
- Tips on how to use your ranking to tell a unique and compelling story in your marketing, benchmarking and hiring processes
- Rosettes
- Certificate of Achievement
- Press release